SCHEMBL5182671

SCHEMBL5182671

NS(=O)(=O)c1ccc2c(c1)/C(=C\c1c[nH]c3ccccc13)C(=O)N2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 9/20 1.00
▸ SYK P43405 5/20 1.00
▸ NTRK3 Q16288 5/20 0.71
▸ NTRK2 Q16620 5/20 0.71
▸ KDR P35968 4/20 0.67
▸ RET P07949 3/20 0.67
▸ PDGFRB P09619 3/20 0.67
▸ PRKD3 O94806 2/20 0.67
▸ ABL1 P00519 2/20 0.67
▸ LTK P29376 2/20 0.67
▸ FLT3 P36888 2/20 0.67
▸ CSNK1A1 P48729 2/20 0.67
▸ CDK7 P50613 2/20 0.67
▸ MAP2K1 Q02750 2/20 0.67
▸ MST1R Q04912 2/20 0.67
▸ AURKB Q96GD4 2/20 0.67
▸ CLK4 Q9HAZ1 2/20 0.67
▸ ALK Q9UM73 2/20 0.67
▸ DAPK3 O43293 1/20 0.67
▸ MAP4K4 O95819 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5182676 1.00 NTRK1 (1.00) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL5181885 0.89 NTRK1 (0.80) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL5843067 0.89 NTRK1 (0.80) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL8583220 0.87 NTRK1 (0.77) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL8583222 0.87 NTRK1 (0.77) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL18546657 0.86 NTRK1 (1.00) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL5181556 0.86 NTRK1 (0.76) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL5420371 0.86 NTRK1 (0.76) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL5181559 0.86 NTRK1 (0.76) NTRK1SYKNTRK3NTRK2KDR
SCHEMBL5420368 0.86 NTRK1 (0.76) NTRK1SYKNTRK3NTRK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 — — US claimed
US-6706709-B2 TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER SUGEN, INC. 2004-03-16 — — US claimed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 — — EP claimed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 — — US claimed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 — — WO claimed
US-5840745-A INHIBITING CELL PROLIFERATION, TUMOR GROWTH, METASTASIS, DEVELOPMENT OF ATHEROMATOUS PLAQUE AND RESTENOSIS, CONTROLLING ANGIOGENESIS, TREATING DIABETES, ENHANCING CANCER THERAPY PHARMACIA S. P. A. (IT) 1998-11-24 — — US claimed
WO-1996022976-A1 HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS PHARMACIA S.P.A. (IT) 1996-08-01 — — WO claimed
US-20070213403-A1 TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS FORSKARPATENT I SYD AB (SE) 2007-09-13 — — US disclosed
EP-1773309-A1 TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS Forskarpatent i Syd AB (SE) 2007-04-18 — — EP disclosed
US-7071332-B2 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. (US) 2006-07-04 — — US disclosed
WO-2006004545-A1 TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS FORSKARPATENT I SYD AB (SE) 2006-01-12 — — WO disclosed
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 — — US disclosed
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 — — US disclosed
US-6706709-B2 TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER SUGEN, INC. 2004-03-16 — — US disclosed
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 — — US disclosed
US-6531502-B1 Antitumor SUGEN, INC. 2003-03-11 — — US disclosed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 — — US disclosed
US-5840745-A INHIBITING CELL PROLIFERATION, TUMOR GROWTH, METASTASIS, DEVELOPMENT OF ATHEROMATOUS PLAQUE AND RESTENOSIS, CONTROLLING ANGIOGENESIS, TREATING DIABETES, ENHANCING CANCER THERAPY PHARMACIA S. P. A. (IT) 1998-11-24 — — US disclosed
EP-0752985-A1 HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS PHARMACIA & UPJOHN S.p.A. (IT) 1997-01-15 — — EP disclosed
WO-1996022976-A1 HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS PHARMACIA S.P.A. (IT) 1996-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase DMPK, MAP4K3, MAP3K20 NTRK1 664/4885SYK 744/4885NTRK3 609/4885
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 NTRK1 1206/4885SYK 878/4885NTRK3 1341/4885
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 NTRK1 1206/4885SYK 878/4885NTRK3 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback